Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
During five years of observation of all persons with T2D in Denmark, use of once-weekly semaglutide independently more than doubled the risk of NAION. Given the irreversible nature of NAION, it is important to acknowledge this risk, and upcoming studies should aim to identify high-risk subgroups.
Authors
- Jakob Grauslund (ORCID: https://orcid.org/0000-0001-5019-0736)
- Ryo Kawasaki (ORCID: https://orcid.org/0000-0002-7492-6303)
- Kurt Højlund (ORCID: https://orcid.org/0000-0002-0891-4224)
- Laleh Dehghani Molander
- Sören Möller (ORCID: https://orcid.org/0000-0003-0858-4269)
- Andreas Abou Taha
- Lonny Stokholm (ORCID: https://orcid.org/0000-0002-9727-6649)
Institutions
- Steno Diabetes Centers (DK)
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
Publication Details
- Journal
- International Journal of Retina and Vitreous
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s40942-024-00620-x
- Citations
- 51
- Primary Topic
- Intraoperative Neuromonitoring and Anesthetic Effects
- Type
- article
- Field-Weighted Citation Impact
- 29.21